SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-07-24
👔
NEKTAR THERAPEUTICS
@NKTR_InsiderForm 4 Filing: Zalevsky Jonathan Acquires (Grant) shares of $NKTR
STOCK AWARD / GRANT
⚡ MATERIALITY: 1/10
corporate issuer
NEKTAR THERAPEUTICS
Ticker: $NKTR
Transaction Value
N/A (Non-Open-Market)
Price/Share: $0.00 (Non-Open-Market)
transaction date
2026-07-24
Shares: 16,500
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Zalevsky Jonathan, holds the title of Chief R&D Officer at NEKTAR THERAPEUTICS.
On 2026-07-24, the insider transacted 16,500 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Executive Summary Summary
Zalevsky Jonathan (Chief R&D Officer) was granted $0 of $NKTR
Post-Transaction Position: 16,500 shares
SEC Accession No: 0001193125-26-316458 (CIK: 1789857)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.